Vaccine manufacturers are adapting rapidly to the challenges posed by Omicron. Companies like Pfizer and Moderna have announced that they can update their mRNA vaccines within months if necessary. Meanwhile, traditional vaccine manufacturers are also exploring ways to enhance their formulations to tackle Omicron effectively.
